Radioimmunotherapy of non-Hodgkin's lymphoma: From the 'magic bullets' to 'radioactive magic bullets'

Yale Journal of Biology and Medicine

Volumn 84, Issue 4, 2011, Pages 391-407

  Chamarthy, Murthy R ^a   Williams, Scott C ^a   Moadel, Renee M ^b  

^a BRIDGEPORT HOSPITAL   (United States)

^b MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

Alpha particle; Auger; Beta particle; Bexxar; Biodistribution; Dosimetry; Hodgkin's lymphoma; Immunotherapy; Lymphoma; Monoclonal antibody; Non Hodgkin's lymphoma; Radioimmunotherapy; Rituximab; Y 90; Zevalin

Indexed keywords

ANTINEOPLASTIC AGENT; CD20 ANTIBODY; CD20 ANTIBODY I 131; CD20 ANTIBODY Y 90; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPRATUZUMAB TETRAXETAN Y 90; FLUDARABINE; IBRITUMOMAB TIUXETAN; IMMUNOMODULATING AGENT; MONOCLONAL ANTIBODY LYM 1; MONOCLONAL ANTIBODY NLS 7G3 IN 111; PREDNISONE; RITUXIMAB; TOSITUMOMAB; TOSITUMOMAB I 131; UNCLASSIFIED DRUG; VINCRISTINE;

ABDOMINAL PAIN; ACUTE GRANULOCYTIC LEUKEMIA; ANEMIA; B CELL LYMPHOMA; BLOOD TOXICITY; CHILL; DOSIMETRY; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FEVER; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG RESPONSE; DRUG TARGETING; FLU LIKE SYNDROME; FOLLICULAR LYMPHOMA; HUMAN; HYPOTHYROIDISM; INFECTION; KIDNEY FUNCTION; LARGE CELL LYMPHOMA; LEUKEMIA; LIVER DISEASE; LYMPHOCYTOMA; MARGINAL ZONE LYMPHOMA; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; RADIATION SAFETY; RADIOIMMUNOTHERAPY; REVIEW; SCINTIGRAPHY; SIDE EFFECT; SKIN TOXICITY; THROMBOCYTOPENIA;

ANTIBODIES, MONOCLONAL; HUMANS; LYMPHOMA, NON-HODGKIN; RADIOIMMUNOTHERAPY;

EID: 84863393240     PISSN: 00440086     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. Goldsmith SJ. Radioimmunotherapy of lymphoma: Bexxar and Zevalin. Semin Nucl Med. 2010;40(2):122-35.
2. Kassis AI, Adelstein SJ. Radiobiologic principles in radionuclide therapy. J Nucl Med. 2005;46(Suppl 1):4S-12S.
3. Kassis AI. Therapeutic Radionuclides: Biophysical and Radiobiologic Principles. Semin Nucl Med. 2008;38(5):358-66.
4. Dixon KL. The radiation biology of radioimmunotherapy. Nucl Med Commun. 2003;24(9):951-7.
5. American Cancer Society. Cancer Facts & Figures 2010 [Internet]. Cited 2011 Sep 10. Available from: http://www.cancer.org/acs/groups/content/@ nho/documents/document/acspc-024113.pdf.
6. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, et al. The World Health Organization classification of hematological malignancies report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Mod Pathol. 2000;13(2):193-207.
7. Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol. 1989;7(11):1630-6.
8. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993;329(14):987-94.
9. Pressman D, Korngold L. The in vivo localization of anti-Wagner-osteogenic sarcoma antibodies. Cancer. 1953;6(3):619-23.
10. Beierwaltes WH. Radioiodine-labeled compounds previously or currently used for tumour localization with radioactive agents. IAEA Advisory Group on Tumor Localization with Radioactive Agents; 1974 Dec 9-14. IAEA, Vienna. MG-50/2, pp. 47-56.
11. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256(5517):495-7.
12. DeNardo SJ, DeNardo GL, O'Grady LF, Macey DJ, Mills SL, Epstein AL, et al. Treatment of a patient with B cell lymphoma by I-131 LYM-1 monoclonal antibodies. Int J Biol Markers. 1987;2(1):49-53.
13. Nadler LM, Stashenko P, Hardy R, Kaplan WD, Button LN, Kufe DW, et al. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res. 1980;40(9):3147-54.
14. Parker BA, Vassos ABSE, Miller RA, Hupf H, Amox DG, et al. Radioimmunotherapy of human B-cell lymphoma with 90Y-conjugated anti-idiotype monoclonal antibody. Cancer Res. 1990;50(3 Suppl):1022s-1028s.
15. Anderson KC, Bates MP, Slaughenhoupt BL, Pinkus GS, Schlossman SF, Nadler LM. Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood. 1984;63(6):1424-33.
16. Tedder T, Boyd A, Freedman A, Nadler LM, Schlossman SF. The B cell surface molecule is functionally linked with B cell activation and differentiation. J Immunol. 1985;135(2):973-9.
17. Press OW, Howell-Clark J, Anderson S, Bernstein I. Retention of B-cell-specific monoclonal antibodies by human lymphoma cells. Blood. 1994;83(5):1390-7.
18. Cardarelli PM, Quinn M, Buckman D, Fang Y, Colcher D, King DJ, et al. Binding to CD20 by anti-B1 antibody or F(ab')(2) is sufficient for induction of apoptosis in B-cell lines. Cancer Immunol Immunother. 2002;51(1):15-24.
19. Zevalin [package insert]. Spectrum Pharmaceuticals Inc. [Internet]. 2009. Cited 2011 Sep 10. Available from: http://www.zevalin. com/v3/pdf/Zevalin_Package_Insert.pdf
20. Bexxar [package insert]. GlaxoSmithKline [Internet]. 2005. Cited 2011 Sep 10. Available from: http://us.gsk.com/products/assets/ us_bexxar.pdf.
21. Zelenetz AD. Radioimmunotherapy for lymphoma. Curr Opin Oncol. 1999;11(5):375-80.
22. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a fourdose treatment program. J Clin Oncol. 1998;16(8):2825-33.
23. Coiffer B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235-42.
24. Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan RIT versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2002;20(10):2453-63.
25. Morschauer F, Radford J, Van Hoff A, Vitolo U, Soubeyran P, Tilly H, et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol. 2008;26(32):5156-64.
26. Kaminski MS, Zelenetz AD, Press OW, Saleh M, Leonard J, Fehrenbacher L, et al. Pivotal study of iodine I-131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol. 2001;19(19):3918-28.
27. Davis TA, Kaminski MS, Leonard J. Longterm results of a randomized trial comparing tositumomab and iodine-131 tositumomab with tositumomab alone in patients with relapsed or refractory low-grade or transformed low grade non-Hodgkin's lymphoma. Proc Am Soc Hematol. 2003;102:405a.
28. Kaminski MS, Tuck M, Estes J, Kolstad A, Ross CW, Zasadny K, et al. I-131 tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med. 2005; 352(5):441-9.
29. Leonard JP, Coleman M, Kostakoglu L, Chadburn A, Cesarman E, Furman RR, et al. Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I-131 tositumomab for untreated follicular lymphoma. J Clin Oncol. 2005;23(24):5696-704.
30. Witzig TE, Flinn IW, Gordon LI, Emmanouilides C, Czuczman MS, Saleh MN, et al. Treatment with ibritumomab tiuxetan RIT in patients with rituximab refractory follicular non-Hodgkin's lymphoma. J Clin Oncl. 2002;20(15):3262-9.
31. Fisher RI, Kaminski MS, Wahl RL, Knox SJ, Zelenetz AD, Vose JM, et al. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol. 2005;23(30):7565-73.
32. Wagner HN, Wiseman GA, Marcus CS, Nabi HA, Nagle CE, Fink-Bennett DM, et al. Administration guidelines for RIT with Y-90 labeled anti-CD20 monoclonal antibody. J Nucl Med. 2002;43(2):267-72.
33. Gregory SA, Leonard JP, Knox SJ, Zelenetz DA, Armitage J, Kaminiski M. The iodine I-131 tositumomab therapeutic regimen: Summary of safety in 995 patients with relapsed/refractory low grade (LG) and transformed LG non-Hodgkin's lymphoma (NHL). J Clin Oncol. 2004;22(14S):6732 (Abstr).
34. Goldenberg DM. Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med. 2002;43(5):693-713.
35. Wahl RL. Tositumomab 131I therapy in non-Hodgkin's lymphoma. J Nucl Med. 2005;46(1 suppl):128S-40S.
36. Zanzonico PB, Binkert BL, Goldsmith SJ. Bremsstrahlung radiation exposure from pure beta-ray emitters. J Nucl Med. 1999;40(6):1024-8.
37. Wiseman G, Leigh B, Witzig T, Gansen D, White C. Radiation exposure is very low to the family members of patients treated with yttrium-90 Zevalin anti-CD20 monoclonal antibody therapy for lymphoma. Eur J Nucl Med. 2001;28:1198 (abstr).
38. Rutar FJ, Augustine SC, Colcher D, Siegel JA, Jacobson DA, Tempero MA, et al. Outpatient treatment with 131 I-anti-B1 antibody: Radiation exposure to family members. J Nucl Med. 2001;42(6):907-15.
39. Cheson BD. The International Harmonization Project for response criteria in lymphoma clinical trials. Hematol Oncol Clin North Am. 2007;21(5):841-54.
40. Ansell SM, Schilder RJ, Pieslor PC, Gordon LI, Emmanouilides C, Vo K, et al. Antilymphoma treatments given subsequent to yttrium-90 ibritumomab tiuxetan are feasible in patients with progressive non-Hodgkin's lymphoma: A review of the literature. Clin Lymphoma. 2004;5(3):202-4.
41. Dosik AD, Coleman M, Kostakoglu L, Furman RR, Fiore JM, Muss D, et al. Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphoma. Cancer. 2006;106(3):616-22.
42. Leonard JP, Siegel JA, Goldsmith SJ. Comparative physical and pharmacologic characteristics of iodine-131 and yttrium-90: Implications for RIT for patients with non-Hodgkin's lymphoma. Cancer Invest. 2003;21(2):241-52.
43. Polyak MJ, Deans JP. Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure. Blood. 2002;99(9):3256-62.
44. Teeling JL, Mackus WJ, Wiegman LJ, van den Brakel JH, Beers SA, French RR. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol. 2006;177(1):362-71.
45. Arico D, Grana CM, Vanazzi A, Ferrari M, Mallia A, Sansovini M, et al. The role of dosimetry in the high activity 90Y-ibritumomab tiuxetan regimens: Two cases of abnormal biodistribution. Cancer Biother Radiopharm. 2009;24(2):271-5.
46. Lin F, Iagaru A. Current concepts and future directions in RIT. Curr Drug Discov Technol. 2010;7(4):253-62.
47. Schaefer NG, Ma J, Huang P, Buchanan J, Wahl RL. Radioimmunotherapy in non-Hodgkin lymphoma: opinions of U.S. medical oncologists and hematologists. J Nucl Med. 2010;51(6):987-94.
48. Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, Leblanc M, et al. Phase II trial of CHOP chemotherapy followed by tositumomab/ iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol. 2006;24(25):4143-9.
49. DeNardo G, DeNardo S. Dose intensified molecular targeted radiotherapy for cancer-lymphoma as a paradigm. Semin Nucl Med. 2010;40(2):136-44.
50. Press OW, Eary JF, Appelbaum FR, Martin PJ, Nelp WB, Glenn S, et al. Phase II trial of 131IB1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet. 1995;346(8971):336-40.
51. Press OW, Eary JF, Gooley T, Gopal AK, Liu S, Rajendran JG, et al. A phase I/II trial of iodine-131 tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood. 2000;96(9):2934-42.
52. DeNardo GL, Schlom J, Buchsbaum DJ, Meredith RF, O'Donoghue JA, Sgouros G, et al. Rationales, evidence and design considerations in fractionated RIT. Cancer. 2002;94(4 Suppl):1332-48.
53. Morschhauser F, Kraeber-Bodéré F, Wegener WA, Harousseau JL, Petillon MO, Huglo D, et al. High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphoma. J Clin Oncol. 2010;28(23):3709-16.
54. Weiden PL, Breitz HB. Pretargeted RIT (PRIT) for treatment of non-Hodgkin's lymphoma (NHL). Crit Rev Oncol Hematol. 2001;40(1):37-51.
55. Press OW, Corcoran M, Subbiah K, Hamlin DK, Wilbur DS, Johnson T, et al. A comparative evaluation of conventional and pretargeted RIT of CD20-expressing lymphoma xenografts. Blood. 2001;98(8):2535-43.
56. Zalutsky MR. Targeted alpha-particle therapy of microscopic disease: Providing a further rationale for clinical investigation. J Nucl Med. 2006;47(8):1238-40.
57. Brechbiel MW. Targeted alpha-therapy: past, present, future? Dalton Trans. 2007;21(43):4918-28.
58. Tavares AA, Tavares JM. Evaluating 99m-Tc Auger electrons for targeted tumor radiotherapy by computational methods. Med Phys. 2010;37(7):3551-9.
59. Leyton JV, Hu M, Gao C, Turner PV, Dick JE, Minden M, et al. Auger Electron Radioimmunotherapeutic Agent Specific for the CD123+/CD131-Phenotype of the Leukemia Stem Cell Population. J Nucl Med. 2011;52(9):1465-73.
60. Karagiannis TC. Comparison of different classes of radionuclides for potential use in RIT. Hell J Nucl Med. 2007;10(2):82-8.
61. Park SI, Shenoi J, Pagel JM, Hamlin DK, Wilbur DS, Orgun N, et al. Conventional and pretargeted RIT using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease. Blood. 2010;116(20):4231-9.
62. Dadachova E, Casadevall A. RIT of infectious diseases. Semin Nucl Med. 2009;39(2):146-53.
63. Meredith RF, Alvarez RD, Partridge EE, Khazaeli MB, Lin CY, Macey DJ, et al. Intraperitoneal radioimmunochemotherapy of ovarian cancer: A phase I study. Cancer Biother Radiopharm. 2001;16(4):305-15.
64. Liersch T, Meller J, Kulle B, Behr TM, Markus P, Langer C, et al. Phase II trial of carcinoembryonic antigen RIT with I-131 Labetuzumab after salvage resection of colorectal metastases in the liver: Five-year safety and efficacy results. J Clin Oncol. 2005;23(27):6763-70.
65. Kassis AI. Molecular and cellular radiobiological effects of Auger emitting radionuclides. Radiat Prot Dosimetry. 2011;143(2-4):241-7.
66. Baranowska-Kortylewicz J. Intraperitoneal radioimmunotherapy: Auger electron emitters for solid tumors. Immunotherapy. 2001;3(4):491-4.
67. Sharkey RM, Karacay H, Goldenberg DM. Improving the treatment of non-Hodgkin lymphoma with antibody-targeted radionuclides. Cancer. 2010;116(4 Suppl):1134-45.
68. Balhorn R, Hok S, Burke PA, Lightstone FC, Cosman M, Zemla A, et al. Selective high affinity ligand antibody mimics for cancer diagnosis and therapy: Initial application to lymphoma/leukemia. Clin Cancer Res. 2007;13(s18):5621s-5628s.
69. DeNardo GL, Mirick GR, Hok S, DeNardo SJ, Beckett LA, Adamson GN, et al. Molecular specific and cell selective cytotoxicity induced by a novel synthetic HLA-DR antibody mimic for lymphoma and leukemia. Int J Oncol. 2009;34(2):511-6.